Clinical Trials Logo

Clinical Trial Summary

Botulinum type A (BTX-A) is an easy and efficacious treatment for gingival smile (GS). However, the necessary for higher-doses among patients are controversial. The objective was to compare the reduction of gingival exposure using two methods in patients with different dosage. In this prospective self-controlled study, healthy GS participates who had an anterior gingival exposure (GE) of more than 3 mm were enrolled and administered with 2-5 U BTX-A (total, 4-10 U) injections into 1-2 points according to the severity presented pretreatment in the Average-dose Method. And after 8 months, the Higher-doses Method was administered the same point injection of 3-10 U BTX-A (total, 6-20 U). Data were collected at baseline and 4, 12, 32 and 60 weeks of follow-up.


Clinical Trial Description

The smile is one of the universal facial expressions of humans. Gingival smile is characterized by gingival exposure of >3 mm upon smiling. The degree of gingival exposure can vary substantially between patients, with patients presenting gingival exposure of up to more than 10 mm.1,2 The prevalence of gingival smile is 10.57%,3 and it is more frequently observed in females.4,5 Although gingival smile is merely an anatomical variation, it can be considered unattractive, causing significant distress and impacting one's quality of life.6 Moreover, most orthodontists and dentists regard gingival smile as an important risk factor for dental treatment.7 Gingival smile involves a complex interaction between the facial muscles, bone, and skin; specifically, it is related to hypermobility of the upper lip with muscle involvement and alterations in anatomical features, such as a short clinical dental crown, anterior dentoalveolar extrusion, maxillary excess, and a short upper lip.4,8-10 Therapies for gingival smile range from botulinum toxin injections to surgical interventions according to its etiology. Although the outcomes of surgical procedures are long-lasting, botulinum toxin type A treatment is an easy and fast outpatient procedure that requires no downtime and has high efficacy rates.1,11-19 Nevertheless, there are controversies around the optimal dose and injection site of botulinum toxin type A. Moreover, the efficiency of botulinum toxin type A for gingival smile varies markedly between studies, with the improvement rate of gingival exposure ranging from 62.06% to 98%.1,16,19,20 Sucupira and Abramovitz16 advocate the use of a low amount of botulinum toxin type A of 1.95 U per side for the treatment of gingival smile. They noted an average satisfaction level of 9.75 on a 10-point scale with this approach. They claimed that higher doses does not provide further benefit, and, in fact, could lead to lip ptosis, asymmetry, and excessive upper lip length.16 However, Polo13,15,17 disagreed with their argument, claiming 2-5 U injection of botulinum toxin type A according to the severity of gingival smile.15 In this regard, Garcia and Fulton showed that low-dose injection of botulinum toxin per muscle (2-5 IU) was as effective as higher doses.21 Though prior studies have demonstrated a correlation between higher doses of botulinum toxin and intensity and duration of muscle paralyses,22,23 no conclusion can be drawn regarding duration and intensity of doses used in the recent studies. A safe approach advocated by some authors consists of starting with low toxin doses initially, with retouching at a later stage if required.1,24 In this study, we compared botulinum toxin type A efficiency using the average-dose method (2-5 U botulinum toxin type A per side determined according to the severity of anterior gingival smile) and , the higher-dose method (3-10 U botulinum toxin type A per side determined according to the severity of anterior gingival smile). We aimed to assess the efficiency and duration of these approaches, as well as side effects and patients' satisfaction with treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05127018
Study type Interventional
Source Peking University
Contact
Status Completed
Phase Phase 4
Start date November 20, 2019
Completion date October 20, 2021

See also
  Status Clinical Trial Phase
Completed NCT04527744 - Application of Botulinum Toxin at the Yonsei Point for the Treatment of Gummy Smile N/A
Completed NCT02135341 - Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility Phase 2
Completed NCT03508882 - Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Phase 4
Completed NCT03054610 - Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis. Phase 1
Completed NCT00822523 - Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies N/A
Completed NCT04820543 - Effects of Dose and Injection Site for Gummy Smile Treatment With Botulinum Type A Phase 4
Completed NCT03385161 - Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia N/A
Not yet recruiting NCT04580238 - Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache Phase 1